Next-generation sequencing (NGS) has become a key component of molecular testing in both myeloid and lymphoproliferative neoplasms. It can facilitate improvements in diagnostic classification, prognostication and identification of therapeutic targets. In this presentation, hear our expert share the utility of faster molecular results in lymphoid genomic profiling and their experience with the Ion Torrent Genexus System and the Ion AmpliSeq™ Liverpool Lymphoid Network Panel